Abstract
In a retrospective analysis of paediatric renal-transplant recipients receiving basiliximab, we noted significantly increased blood concentrations of cyclosporin, early cyclosporin toxicity, and a lower dose requirement within the first 10 days compared with controls. As the CD25 saturation fades at days 28-50, cyclosporin concentrations decline and 20% higher doses are required to maintain adequate trough concentrations. We suggest that an interleukin-2 receptor-mediated alteration of the cytochrome P450 system causes this systemic drug interaction and propose that the initial ciclosporin dose should be limited to 400 mg/m2 if used in combination with basiliximab.
MeSH terms
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacokinetics
-
Antibodies, Monoclonal / therapeutic use*
-
Basiliximab
-
Case-Control Studies
-
Child
-
Cyclosporine / administration & dosage*
-
Cyclosporine / blood
-
Drug Interactions
-
Half-Life
-
Humans
-
Immunosuppressive Agents / blood
-
Immunosuppressive Agents / immunology
-
Immunosuppressive Agents / pharmacokinetics
-
Immunosuppressive Agents / therapeutic use*
-
Kidney Transplantation*
-
Receptors, Interleukin-2 / drug effects*
-
Receptors, Interleukin-2 / immunology
-
Recombinant Fusion Proteins*
-
Retrospective Studies
Substances
-
Antibodies, Monoclonal
-
Immunosuppressive Agents
-
Receptors, Interleukin-2
-
Recombinant Fusion Proteins
-
Cyclosporine
-
Basiliximab